

UNITED STATES BANKRUPTCY COURT  
FOR THE DISTRICT OF DELAWARE

In re: Orexigen Therapeutics, Inc.

Case No. 18-10518

Debtor(s)

§  
§  
§  
§

Jointly Administered

**Post-confirmation Report**

Chapter 11

Quarter Ending Date: 09/30/2023

Petition Date: 03/12/2018

Plan Confirmed Date: 05/17/2019

Plan Effective Date: 05/31/2019

This Post-confirmation Report relates to:  Reorganized Debtor

Other Authorized Party or Entity: Wind-Down Administrator

Name of Authorized Party or Entity

/s/ Levi Akkerman

Signature of Responsible Party

10/23/2023

Date

Levi Akkerman

Printed Name of Responsible Party

Potter Anderson & Corroon LLP  
1313 N. Market St., 6th Floor,  
Wilmington, DE 19801-6108

Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.



181051823102300000000001

Debtor's Name Orexigen Therapeutics, Inc.

Case No. 18-10518

**Part 1: Summary of Post-confirmation Transfers**

	Current Quarter	Total Since Effective Date
a. Total cash disbursements	\$10,305	\$10,705,448
b. Non-cash securities transferred	\$0	\$0
c. Other non-cash property transferred	\$0	\$0
d. Total transferred (a+b+c)	\$10,305	\$10,705,448

**Part 2: Preconfirmation Professional Fees and Expenses**

a.			Approved Current Quarter	Approved Cumulative	Paid Current Quarter	Paid Cumulative
	Professional fees & expenses (bankruptcy) incurred by or on behalf of the debtor <i>Aggregate Total</i>			\$0	\$100,985	\$0
<i>Itemized Breakdown by Firm</i>						
	Firm Name	Role				
i	Potter Anderson & Corroon LL	Special Counsel	\$0	\$16,280	\$0	\$16,280
ii	Quinn Emanuel Urquhart & Sul	Special Counsel	\$0	\$84,705	\$0	\$84,705
iii						
iv						
v						
vi						
vii						
viii						
ix						
x						
xi						
xii						
xiii						
xiv						
xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						

Debtor's Name Orexigen Therapeutics, Inc.

Case No. 18-10518

xxx						
xxxI						
xxxII						
xxxIII						
xxxIV						
xxxV						
xxxVI						
xxxVII						
xxxVIII						
xxxIX						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						
xlix						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						

Debtor's Name Orexigen Therapeutics, Inc.

Case No. 18-10518

lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						
lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						
xc						
xcii						
xciii						
xciv						
xcv						
xcvi						
xcvii						
xcviii						
xcix						
c						
ci						

			Approved Current Quarter	Approved Cumulative	Paid Current Quarter	Paid Cumulative	
b.	Professional fees & expenses (nonbankruptcy) incurred by or on behalf of the debtor		\$0	\$0	\$0	\$0	
	<i>Aggregate Total</i>						
	<i>Itemized Breakdown by Firm</i>						
		Firm Name	Role				
	i	N/A		\$0	\$0	\$0	\$0
	ii						
	iii						
iv							
v							
vi							

Debtor's Name Orexigen Therapeutics, Inc.

Case No. 18-10518

vii						
viii						
ix						
x						
xi						
xii						
xiii						
xiv						
xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						
xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						
xxxvii						
xxxviii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						

Debtor's Name Orexigen Therapeutics, Inc.

Case No. 18-10518

xlix						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						
lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						

Debtor's Name Orexigen Therapeutics, Inc.

Case No. 18-10518

xcvii						
xcviii						
xcvix						
xcvi						
xcv						
xciv						
xciii						
xcii						
xcv						
xciv						
xcv						
xcvi						
xcvii						
xcviii						
xcvix						
c						
ci						
c.	All professional fees and expenses (debtor & committees)		\$0	\$100,985	\$0	\$100,985

**Part 3: Recoveries of the Holders of Claims and Interests under Confirmed Plan**

	Total Anticipated Payments Under Plan	Paid Current Quarter	Paid Cumulative	Allowed Claims	% Paid of Allowed Claims
a. Administrative claims	\$0	\$0	\$0	\$192,468	0%
b. Secured claims	\$1,163,878	\$0	\$8,537,068	\$165,000,000	5%
c. Priority claims	\$90,795	\$0	\$90,795	\$0	0%
d. General unsecured claims	\$655,596	\$0	\$464,225	\$93,109,625	0%
e. Equity interests	\$0	\$0	\$0		

**Part 4: Questionnaire**a. Is this a final report? Yes  No 

If yes, give date Final Decree was entered: \_\_\_\_\_

If no, give date when the application for Final Decree is anticipated: 12/31/2023b. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes  No

Debtor's Name Orexigen Therapeutics, Inc.

Case No. 18-10518

**Privacy Act Statement**

28 U.S.C. § 589b authorizes the collection of this information and provision of this information is mandatory. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6) and to otherwise evaluate whether a reorganized chapter 11 debtor is performing as anticipated under a confirmed plan. Disclosure of this information may be to a bankruptcy trustee when the information is needed to perform the trustee's duties, or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." *See* 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: [http://www.justice.gov/ust/eo/rules\\_regulations/index.htm](http://www.justice.gov/ust/eo/rules_regulations/index.htm). Failure to provide this information could result in the dismissal or conversion of your bankruptcy case, or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

**I declare under penalty of perjury that the foregoing Post-confirmation Report and its attachments, if any, are true and correct and that I have been authorized to sign this report.**

/s/ Peter Kravitz

\_\_\_\_\_  
Signature of Responsible Party

Wind Down Administrator

\_\_\_\_\_  
Title

Peter Kravitz

\_\_\_\_\_  
Printed Name of Responsible Party


10/23/2023

\_\_\_\_\_  
Date




Debtor's Name Orexigen Therapeutics, Inc.


Case No. 18-10518




Page 1



Other Page 1



Page 2 Minus Tables



Bankruptcy Table 1-50

Debtor's Name Orexigen Therapeutics, Inc.

Case No. 18-10518

Bankruptcy Table 51-100

Non-Bankruptcy Table 1-50

Non-Bankruptcy Table 51-100

Part 3, Part 4, Last Page

*In re Orexigen Therapeutics, Inc*  
Case No. 18-10518 (KG)

Notes to Post-Confirmation Report for the Quarter Ended **September 30th**

Part 2b

The Wind Down Administrator has not made any payments on account of pre-confirmation professional fees and expenses.

Part 3

“Total Anticipated Payments Under Plan” reflects amounts paid plus cash on hand as of the date of this report, and is subject to reduction based on, among other things, operating expenses of the Wind Down Administrator and/or the estates. The claims reconciliation process is ongoing and reporting with respect to “Allowed Claims” is premature at this time. Accordingly, all of the amounts listed with respect to “Allowed Claims” of all priority levels reflect the estimates set forth in the Disclosure Statement and any and all amounts are subject to change as the reconciliation process evolves. Therefore, the “% Paid of Allowed Claims” may be inaccurate as a result.